Efficacy and Clinical Outcomes of Levosimendan in E-CPR (ECPR)

Hamad Medical Corporation (HMC)

Status: Enrolling

Conditions: Extracorporeal Membrane Oxygenation Complication; Cardiogenic Shock

Treatments: Drug: Levosimendan

Study type: Observational

Funder types: Industry

Identifiers

NCT05730907

MRC-01-21-282

Details and patient eligibility

About

Treatment of refractory cardiac arrest requiring cardiopulmonary resuscitation (CPR) may be augmented with Extracorporeal membrane oxygenation (ECMO) to re-establish perfusion in the absence of return of spontaneous circulation. Literature has demonstrated that ECMO initiated during advanced cardiopulmonary life support may confer superior survival rates with acceptable survival and a relatively low incidence of significant neurologic impairment. Levosimendan has not been investigated in patients with cardiac arrest who underwent Extracorporeal CPR (E-CPR). The current study aims to examine whether levosimendan use in the aforementioned patient population could improve survival and ECMO parameters.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

IInclusion criteria:

• Hospitalized patients ≥ 18 years of age at the time of E-CPR use
• Patients suffered cardiac arrest (IHCA or OHCA)
• Patients received VA-ECMO for E-CPR
• Criteria as per HMC's Extracorporeal Membrane Oxygenation (ECMO) for Cardiac Arrest (E-CPR) clinical practice guidelines (attached with the study protocol)

Exclusion criteria:

• Patients with incomplete key data
• Criteria as per HMC's Extracorporeal Membrane Oxygenation (ECMO) for Cardiac Arrest (E-CPR) clinical practice guidelines (attached with the study protocol)